GlaxoSmithKline (GSK) entered into a strategic alliance with Dong-A Pharmaceuticals Co., Ltd. (Dong-A), the number one pharmaceutical and OTC Company in South Korea.

Merck & Co., Inc. (NYSE: MRK) hosted its first R&D and Business Briefing since completion of the Merck and Schering-Plough merger and outlined the company's strategy to drive global business growth.

Further strengthening its global competitive position, Abbott (NYSE: ABT) announced a licensing and supply agreement with Zydus Cadila of India for a portfolio of pharmaceutical products that Abbott will commercialize in 15 emerging markets, enabling the company to further accelerate its emerging markets growth.

GlaxoSmithKline (NYSE: GSK) participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines.

Roche announced the launch of the EDUCARE (EDUcation for Cancer in African REgions) project, which, in concert with IAEA (International Atomic Energy Agency), will provide support to help combat the growing cancer epidemic in sub-Saharan Africa.

Bayer Schering Pharma AG, Germany, has started to enroll patients in an international Phase III trial to evaluate its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.

Bayer Schering Pharma AG, Germany, has started to enroll patients in an international Phase III trial to evaluate its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.